Makerere University Research Repository >
College of Health Sciences >
School of Health Sciences >
Research Articles (Health-Sciences) >
Please use this identifier to cite or link to this item:
|Title: ||Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda|
|Authors: ||Bakyaita, Nathan|
Staedke, Sarah G.
Kamya, Moses R.
Rosenthal, Philip J.
Global health problems
East African Network for Monitoring Antimalarial Treatment (EANMAT)
|Issue Date: ||2005 |
|Publisher: ||The American Society of Tropical Medicine and Hygiene|
|Citation: ||Bakyaita, N., Dorsey, G., Adoke, Y., Banek, K., Staedke, S.G., Kamya, M.R., Talisuna, A., Kironde, F., Nsobya, S.L., Kilian, A., Reingold, A., Rosenthal, P.J., Wabwire-Mangen, F. (2005), Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. American Journal of Tropical Medicine and Hygiene, 72(5)|
|Abstract: ||The use of combinations of inexpensive drugs for the treatment of malaria in Africa has been proposed as an interim policy while awaiting the widespread availability of more effective regimens. We compared sulfadoxinepyrimethamine plus chloroquine or amodiaquine in three districts in Uganda. Patients aged 6 months or greater with uncomplicated falciparum malaria were enrolled and randomized to therapy. Safety, tolerability, and efficacy outcomes, adjusted by genotyping, were assessed over 28 days. Of 1,105 patients enrolled, 1,057 (96%) completed follow-up. For children less than 5 years old, the risk of clinical treatment failure adjusted by genotyping at the three sites ranged from 34% to 67% with chloroquine plus sulfadoxine-pyrimethamine and from 13% to 35% with amodiaquine plus sulfadoxine-pyrimethamine (risk differences 21–32%, P < 0.0001 at all sites). Serious adverse events were uncommon with both regimens. The risk of treatment failure with chloroquine plus sulfadoxine-pyrimethamine, the current standard in Uganda, was unacceptably high. Amodiaquine plus sulfadoxine-pyrimethamine was significantly more efficacious; however, existing levels of resistance raises concern about the useful therapeutic life-span of this regimen.|
|Appears in Collections:||Research Articles (Health-Sciences)|
Files in This Item:
All items in DSpace are protected by copyright, with all rights reserved.